Laura Chico, PH.D.

Managing Director, Equity Research


Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease.

Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.


Laura’s Edge: Her combination of scientific, research, and academic communities experiences, gives Laura a deeper understanding and ability to translate complex data sets for investors.


  • Aerovate Therapeutics, Inc. (AVTE)
  • Apellis Pharmaceuticals, Inc. (APLS)
  • Aptinyx Inc (APTX)
  • Ardelyx (ARDX)
  • Astria Therapeutics (ATXS)
  • Biogen, Inc. (BIIB)
  • Denali Therapeutics (DNLI)
  • Dianthus Therapeutics, Inc. (DNTH)
  • Edgewise Therapeutics Inc (EWTX)
  • Gossamer Bio (GOSS)
  • Karuna Therapeutics Inc. (KRTX)
  • Neurocrine Biosciences, Inc. (NBIX)
  • Ovid Therapeutics, Inc. (OVID)
  • Passage Bio (PASG)
  • PepGen Inc. (PEPG)
  • Pharvaris N. V. (PHVS)
  • Praxis Precision Medicines, Inc. (PRAX)
  • Sage Therapeutics, Inc. (SAGE)
  • Stoke Therapeutics (STOK)
  • Travere Therapeutics (TVTX)
  • Ultragenyx Pharmaceutical Inc (RARE)
  • Vigil Neuroscience, Inc. (VIGL)
  • Viridian Therapeutics, Inc. (MGEN)
  • Voyager Therapeutics, Inc. (VYGR)
  • Xenon Pharmaceuticals (XENE)